CKD Bio Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CKD Bio.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 34.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CKD Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | 159,935 | -23,130 | -25,355 | -16,588 | N/A |
| 6/30/2023 | 155,183 | -20,233 | -20,483 | -11,038 | N/A |
| 3/31/2023 | 152,876 | -18,403 | -15,290 | -8,075 | N/A |
| 12/31/2022 | 156,042 | -16,703 | -10,435 | -3,205 | N/A |
| 9/30/2022 | 154,395 | -10,462 | -6,837 | 1,239 | N/A |
| 6/30/2022 | 154,759 | -11,222 | -10,230 | 721 | N/A |
| 3/31/2022 | 155,569 | -5,821 | -15,703 | -436 | N/A |
| 12/31/2021 | 142,238 | -6,577 | -26,588 | -5,882 | N/A |
| 9/30/2021 | 135,760 | -6,730 | -30,532 | -7,506 | N/A |
| 6/30/2021 | 130,483 | -1,111 | -40,416 | -6,503 | N/A |
| 3/31/2021 | 127,741 | 1,771 | -52,783 | -3,114 | N/A |
| 12/31/2020 | 124,600 | 6,207 | -57,785 | 4,824 | N/A |
| 9/30/2020 | 135,773 | 10,664 | -61,903 | 6,278 | N/A |
| 6/30/2020 | 138,042 | 12,633 | -56,651 | 10,401 | N/A |
| 3/31/2020 | 136,265 | 12,446 | -36,094 | 19,449 | N/A |
| 12/31/2019 | 137,184 | 12,265 | -30,817 | 16,990 | N/A |
| 9/30/2019 | 129,529 | 10,563 | -27,627 | 19,152 | N/A |
| 6/30/2019 | 127,134 | 9,605 | -13,990 | 19,668 | N/A |
| 12/31/2018 | 124,510 | 7,956 | -1,477 | 15,536 | N/A |
| 9/30/2013 | 107,444 | 2,379 | N/A | 13,846 | N/A |
| 6/30/2013 | 113,754 | 4,314 | N/A | 21,211 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A063160's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if A063160's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A063160's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A063160's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A063160's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A063160's Return on Equity is forecast to be high in 3 years time